Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 629

1.

Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.

Ganie MA, Khurana ML, Nisar S, Shah PA, Shah ZA, Kulshrestha B, Gupta N, Zargar MA, Wani TA, Mudasir S, Mir FA, Taing S.

J Clin Endocrinol Metab. 2013 Sep;98(9):3599-607. doi: 10.1210/jc.2013-1040. Epub 2013 Jul 11.

PMID:
23846820
2.

Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.

Diri H, Karaburgu S, Acmaz B, Unluhizarci K, Tanriverdi F, Karaca Z, Kelestimur F.

Gynecol Endocrinol. 2016;32(1):42-5. doi: 10.3109/09513590.2015.1080679. Epub 2015 Sep 15.

PMID:
26370923
3.

Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study.

Ganie MA, Khurana ML, Eunice M, Gupta N, Gulati M, Dwivedi SN, Ammini AC.

J Clin Endocrinol Metab. 2004 Jun;89(6):2756-62. Erratum in: J Clin Endocrinol Metab. 2004 Sep;89(9):4655.

PMID:
15181054
4.

Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.

Wu J, Zhu Y, Jiang Y, Cao Y.

Gynecol Endocrinol. 2008 Jul;24(7):392-8. doi: 10.1080/09513590802217027.

PMID:
18608522
5.

Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.

Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM.

J Clin Endocrinol Metab. 2000 Aug;85(8):2767-74.

PMID:
10946879
6.

Association of oral contraceptive and metformin did not improve insulin resistance in women with polycystic ovary syndrome.

Iwata MC, Porquere L, Sorpreso IC, Baracat EC, Soares Júnior JM.

Rev Assoc Med Bras (1992). 2015 May-Jun;61(3):215-9. doi: 10.1590/1806-9282.61.03.215.

7.

[Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].

Ye BL, Yang HY, Zhao JZ, Lin JJ, Lin WQ.

Zhonghua Fu Chan Ke Za Zhi. 2003 Dec;38(12):745-8. Chinese.

PMID:
14728846
8.

The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.

Yilmaz M, Karakoç A, Törüner FB, Cakir N, Tiras B, Ayvaz G, Arslan M.

Gynecol Endocrinol. 2005 Sep;21(3):154-60.

PMID:
16335907
9.

Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.

Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE.

Fertil Steril. 2004 Oct;82(4):893-902.

PMID:
15482765
10.

Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial.

Fux Otta C, Wior M, Iraci GS, Kaplan R, Torres D, Gaido MI, Wyse EP.

Gynecol Endocrinol. 2010 Mar;26(3):173-8. doi: 10.3109/09513590903215581.

PMID:
20148739
11.

Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.

Pau CT, Keefe C, Duran J, Welt CK.

J Clin Endocrinol Metab. 2014 May;99(5):1870-8. doi: 10.1210/jc.2013-4021. Epub 2014 Feb 25.

12.

Metformin therapy in women with polycystic ovary syndrome.

Aruna J, Mittal S, Kumar S, Misra R, Dadhwal V, Vimala N.

Int J Gynaecol Obstet. 2004 Dec;87(3):237-41.

PMID:
15548396
13.

Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial.

Zheng YH, Wang XH, Lai MH, Yao H, Liu H, Ma HX.

J Altern Complement Med. 2013 Sep;19(9):740-5. doi: 10.1089/acm.2012.0429. Epub 2013 May 15.

PMID:
23676106
15.
16.
17.

Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy.

Berker B, Emral R, Demirel C, Corapcioglu D, Unlu C, Kose K.

Gynecol Endocrinol. 2004 Sep;19(3):125-33.

PMID:
15697073
18.
19.

Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.

Loverro G, Lorusso F, De Pergola G, Nicolardi V, Mei L, Selvaggi L.

Gynecol Endocrinol. 2002 Jun;16(3):217-24.

PMID:
12192894
20.

The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.

Yilmaz M, Biri A, Karakoç A, Törüner F, Bingöl B, Cakir N, Tiras B, Ayvaz G, Arslan M.

J Endocrinol Invest. 2005 Dec;28(11):1003-8.

PMID:
16483179

Supplemental Content

Support Center